Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial

Complementary Therapies in Medicine

Volumn 22, Issue 5, 2014, Pages 851-857

  Panahi, Yunes ^a   Khalili, Nahid ^a   Hosseini, Mahboobeh Sadat ^a   Abbasinazari, Mohammad ^b   Sahebkar, Amirhossein ^c,d  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cardiometabolic syndrome; Curcuma longa; Hypercholesterolemia; Randomized controlled trial; Turmeric

Indexed keywords

ANTILIPEMIC AGENT; CURCUMINOID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIPERINE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ALKALOID; AMIDE; CURCUMIN; PIPERIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HEADACHE; HEALTH CARE QUALITY; HUMAN; IRAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; RASH; BLOOD; MIDDLE AGED;

ADULT; ALKALOIDS; BENZODIOXOLES; CURCUMIN; FEMALE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PIPERIDINES; POLYUNSATURATED ALKAMIDES;

EID: 84908173680     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2014.07.006     Document Type: Article

References (68)

1. Goldenberg R., Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2013, 37:S8-S11.
2. Mathieu P., Pibarot P., Despres J.P. Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manage 2006, 2:285-302.
3. McCullough A.J. Epidemiology of the metabolic syndrome in the USA. J Dig Dis 2011, 12:333-340.
4. Tenenbaum A., Fisman E.Z., Motro M., Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006, 5:20.
5. Hirano T. Metabolic syndrome and small dense LDL-cholesterol. Rinsho Byori - Jpn J Clin Pathol 2007, 55:434-438.
6. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601-1610.
7. Ascaso J., Gonzalez Santos P., Hernandez Mijares A., Mangas Rojas A., Masana L., Millan J., et al. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. Am J Cardiovasc Drugs 2007, 7:39-58.
8. Choi H.D., Shin W.G. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis. Curr Med Res Opin 2014, 30:1-10.
9. Sahebkar A., Watts G.F. Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes Obes Metab 2014, 10.1111/dom.12277.
10. Sahebkar A., Chew G.T., Watts G.F. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 2014, 15:493-503.
11. Sahebkar A., Watts G.F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013, 35:1082-1098.
12. Sahebkar A., Watts G.F. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?. Cardiovasc Drugs Ther 2013, 27:559-567.
13. Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World J Gastroenterol 2011, 17:271-272.
14. Sahebkar A. Citrus auraptene: a potential multifunctional therapeutic agent for nonalcoholic fatty liver disease. Ann Hepatol 2011, 10:575-577.
15. Panahi Y., Pishgoo B., Jalalian H.R., Mohammadi E., Taghipour H.R., Sahebkar A., et al. Investigation of the effects of Chlorella vulgaris as an adjunctive therapy for dyslipidemia: results of a randomised open-label clinical trial. Nutr Diet 2012, 69:13-19.
16. Panahi Y., Ghamarchehreh M.E., Beiraghdar F., Zare M., Jalalian H.R., Sahebkar A. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Hepato-Gastroenterology 2012, 59:2099-2103.
17. Gupta S.C., Patchva S., Aggarwal B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013, 15:195-218.
18. Gupta S.C., Kismali G., Aggarwal B.B. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 2013, 39:2-13.
19. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 2010, 94:e75-e76. [author reply e7].
20. Shehzad A., Lee J., Lee Y.S. Curcumin in various cancers. Biofactors 2013, 39:56-68.
21. Shehzad A., Rehman G., Lee Y.S. Curcumin in inflammatory diseases. Biofactors 2013, 39:69-77.
22. Panahi Y., Sahebkar A., Parvin S., Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012, 49:580-588.
23. Panahi Y., Sahebkar A., Amiri M., Davoudi S.M., Beiraghdar F., Hoseininejad S.L., et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 2012, 108:1272-1279.
24. Strimpakos A.S., Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008, 10:511-545.
25. Panahi Y., Rahimnia A.R., Sharafi M., Alishiri G., Saburi A., Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 2014, 10.1002/ptr.5174.
26. Iranshahi M., Sahebkar A., Hosseini S.T., Takasaki M., Konoshima T., Tokuda H. Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine 2010, 17:269-273.
27. Panahi Y., Saadat A., Beiraghdar F., Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014, 10.1002/ptr.5149.
28. Panahi Y., Saadat A., Beiraghdar F., Hosseini Nouzari S.M., Jalalian H.R., Sahebkar A. Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: a randomized double-blind placebo-controlled trial. J Funct Foods 2014, 6:615-622.
29. Ganjali S., Sahebkar A., Mahdipour E., Jamialahmadi K., Torabi S., Akhlaghi S., et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. The Scientific World Journal 2014, art. no. 898361. 10.1155/2014/898361.
30. Sahebkar A. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin Pharmacol Toxicol 2014, 114:437-438.
31. Shehzad A., Lee Y.S. Curcumin multiple molecular targets mediate multiple pharmacological actions - a review. Drugs Future 2010, 35:113-119.
32. Na L.X., Li Y., Pan H.Z., Zhou X.L., Sun D.J., Meng M., et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res 2013, 57:1569-1577.
33. Chuengsamarn S., Rattanamongkolgul S., Luechapudiporn R., Phisalaphong C., Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012, 35:2121-2127.
34. Bradford P.G. Curcumin and obesity. Biofactors 2013, 39:78-87.
35. Hlavackova L., Janegova A., Ulicna O., Janega P., Cerna A., Babal P. Spice up the hypertension diet - curcumin and piperine prevent remodeling of aorta in experimental L-NAME induced hypertension. Nutr Metab 2011, 8:72.
36. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2013, 28:633-642.
37. Ak T., Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008, 174:27-37.
38. Sahebkar A., Mohammadi A., Atabati A., Rahiman S., Tavallaie S., Iranshahi M., et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 2013, 27:1883-1888.
39. Mohammadi A., Sahebkar A., Iranshahi M., Amini M., Khojasteh R., Ghayour-Mobarhan M., et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 2013, 27:374-379.
40. DiSilvestro R.A., Joseph E., Zhao S., Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 2012, 11:79.
41. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 2014, 11:123.
42. Soni K.B., Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992, 36:273-275.
43. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 2013, 39:197-208.
44. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001, 285:2486-2497.
45. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64:353-356.
46. Zingg J.M., Hasan S.T., Meydani M. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 2013, 39:101-121.
47. Shin S.K., Ha T.Y., McGregor R.A., Choi M.S. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 2011, 55:1829-1840.
48. Kang Q., Chen A. Curcumin inhibits srebp-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1. Endocrinology 2009, 150:5384-5394.
49. Shao W., Yu Z., Chiang Y., Yang Y., Chai T., Foltz W., et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE 2012, 7:e28784.
50. Zhao J., Sun X.B., Ye F., Tian W.X. Suppression of fatty acid synthase, differentiation and lipid accumulation in adipocytes by curcumin. Mol Cell Biochem 2011, 351:19-28.
51. Kim M., Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract 2010, 4:191-195.
52. Prakash U.N., Srinivasan K. Fat digestion and absorption in spice-pretreated rats. J Sci Food Agric 2011, 92:503-510.
53. Baum L., Cheung S.K., Mok V.C., Lam L.C., Leung V.P., Hui E., et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res: Off J Ital Pharmacol Soc 2007, 56:509-514.
54. Usharani P., Mateen A.A., Naidu M.U., Raju Y.S., Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R&D 2008, 9:243-250.
55. Alwi I., Santoso T., Suyono S., Sutrisna B., Suyatna F.D., Kresno S.B., et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 2008, 40:201-210.
56. Ramirez-Bosca A., Soler A., Carrion M.A., Diaz-Alperi J., Bernd A., Quintanilla C., et al. An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech Ageing Dev 2000, 119:41-47.
57. Pungcharoenkul K., Thongnopnua P. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res 2011, 25:1721-1726.
58. Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr 2013, 33:406-414.
59. Sharma R.A., Steward W.P., Gescher A.J. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007, 595:453-470.
60. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
61. Suresh D., Srinivasan K. Tissue distribution and elimination of capsaicin, piperine and curcumin following oral intake in rats. Indian J Med Res 2010, 131:682-691.
62. Wongcharoen W., Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 2009, 133:145-151.
63. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41:40-59.
64. Um M.Y., Hwang K.H., Ahn J., Ha T.Y. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 2013, 113:152-157.
65. Vera-Ramirez L., Perez-Lopez P., Varela-Lopez A., Ramirez-Tortosa M., Battino M., Quiles J.L. Curcumin and liver disease. Biofactors 2013, 39:88-100.
66. Hasan S.T., Zingg J.M., Kwan P., Noble T., Smith D., Meydani M. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 2014, 232:40-51.
67. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
68. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.